Combining forces in metabolic disorders
Altimmune’s early-stage obesity hit is impressive, but big pharma has more advanced rivals.
The big approvals still on the cards for 2021
Biogen’s Aduhelm was the big one, but there are plenty of other key regulatory decisions still pending this year.
Asco 2021 movers – PDS wins, but big pharma reigns
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
Amgen follows Sanofi into a new dermatitis mechanism
The move shines a light on Ichnos, though none of the groups with clinical-stage Ox40 blockers has yet reported full phase 2 data.
Bristol’s buy moves it to the top of the sales charts
The addition of Celgene made Bristol’s sales team pharma’s most productive last year on one measure, but the accolade might be short-lived.
Amgen’s low-dose Kras curveball
The company reveals that it will test a low dose of sotorasib, a move apparently requested by the US FDA.
